Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | CTSC | P53634 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14535742 | 0.80 | CHRNB2 (0.33) | NPSR1CHRNB2CHRNA4ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31673967 | 0.78 | CHRNB2 (0.32) | NPSR1CHRNB2CHRNA4ALDH1A1L3MBTL1 | |
| SCHEMBL901728 | 0.75 | SLC6A9 (0.32) | SLC6A9 | |
| SCHEMBL9738407 | 0.74 | CTSC (0.31) | CTSKCTSC | |
| SCHEMBL2125429 | 0.72 | NPSR1 (0.35) | NPSR1MAPTLMNA | |
| SCHEMBL2125432 | 0.72 | NPSR1 (0.35) | NPSR1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL2123711 | 0.71 | NPSR1 (0.34) | NPSR1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL2124565 | 0.71 | NPSR1 (0.34) | NPSR1MAPTLMNA | |
| SCHEMBL7839416 | 0.70 | CTSC (0.31) | CTSC | |
| SCHEMBL5188438 | 0.69 | NPSR1 (0.39) | NPSR1MAPTALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, ZC3HAV1, NR1H4 | NPSR1 2850/4885MAPT 2107/4885SLC6A9 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.